To be specific, during the early phase of inhibitor treatment, adaptive response would be readjusted to enable tumor cell survival, and increased transcriptional activity of SOX10 is responsible for the upregulation of two cyto-protective factors FOXD3 and SAMMSON, rendering adaptive resistance. The gene discussed is SOX10; the disease is neoplasm.